Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NRAS Q61L |
Therapy | Selumetinib + Venetoclax |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | acute myeloid leukemia | sensitive | Selumetinib + Venetoclax | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) and Venclexta (venetoclax) synergistically inhibited viability of an acute myeloid leukemia cell line harboring NRAS Q61L in culture (PMID: 38456804). | 38456804 |
PubMed Id | Reference Title | Details |
---|---|---|
(38456804) | Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. | Full reference... |